MA34845B1 - Dimaléate de 9-[4-(3-chloro-2- fluoro-phénylamino) -7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one, son utilisation en tant que medicament et sa fabrication - Google Patents

Dimaléate de 9-[4-(3-chloro-2- fluoro-phénylamino) -7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one, son utilisation en tant que medicament et sa fabrication

Info

Publication number
MA34845B1
MA34845B1 MA36143A MA36143A MA34845B1 MA 34845 B1 MA34845 B1 MA 34845B1 MA 36143 A MA36143 A MA 36143A MA 36143 A MA36143 A MA 36143A MA 34845 B1 MA34845 B1 MA 34845B1
Authority
MA
Morocco
Prior art keywords
dimalate
diazaspiro
quinazolin
undecane
phenylamino
Prior art date
Application number
MA36143A
Other languages
English (en)
Inventor
Markus Ostermeier
Waldemar Pfrengle
Guenther Huchler
Peter Sieger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34845B1 publication Critical patent/MA34845B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de la formule (I) qui présente d'excellentes propriétés pharmacologiques, en particulier un effet inhibiteur de la transduction de signal induite par les tyrosines kinase. L'invention concerne également un procédé de préparation stéréosélective de ces composés, notamment pour des formulations pharmaceutiques destinées à être inhalées, et leur utilisation pour le traitement de maladies, notamment de maladies tumorales, de l'hyperplasie bénigne de la prostate et de maladies des poumons et des voies respiratoires.
MA36143A 2011-02-01 2012-01-27 Dimaléate de 9-[4-(3-chloro-2- fluoro-phénylamino) -7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one, son utilisation en tant que medicament et sa fabrication MA34845B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11152895 2011-02-01
PCT/EP2012/051298 WO2012104206A1 (fr) 2011-02-01 2012-01-27 9-[4-(3-chloro-2-fluoro-phényl-amino)-7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one dimaléate, preparation et utilisation du 9-[4-(3-chloro-2-fluoro-phényl-amino)-7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one dimaléate en tant que medicament

Publications (1)

Publication Number Publication Date
MA34845B1 true MA34845B1 (fr) 2014-01-02

Family

ID=43896655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36143A MA34845B1 (fr) 2011-02-01 2012-01-27 Dimaléate de 9-[4-(3-chloro-2- fluoro-phénylamino) -7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one, son utilisation en tant que medicament et sa fabrication

Country Status (23)

Country Link
US (2) US8853225B2 (fr)
EP (1) EP2670736B1 (fr)
JP (1) JP2014504619A (fr)
KR (1) KR20140011330A (fr)
CN (1) CN103608336A (fr)
AP (1) AP3531A (fr)
AR (1) AR085056A1 (fr)
AU (1) AU2012213556A1 (fr)
BR (1) BR112013019416A2 (fr)
CA (1) CA2826193A1 (fr)
CL (1) CL2013002031A1 (fr)
CO (1) CO6781555A2 (fr)
EA (1) EA023573B1 (fr)
EC (1) ECSP13012847A (fr)
GE (1) GEP20156423B (fr)
IL (1) IL227534A0 (fr)
MA (1) MA34845B1 (fr)
MX (1) MX2013008870A (fr)
PE (1) PE20141012A1 (fr)
SG (1) SG192216A1 (fr)
TN (1) TN2013000323A1 (fr)
UY (1) UY33889A (fr)
WO (1) WO2012104206A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289881A1 (fr) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Procédé de synthèse stéréo-sélective d'hétérocycles bi-cycliques
EP2670736B1 (fr) 2011-02-01 2017-03-15 Boehringer Ingelheim International GmbH 9-[4-(3-chloro-2-fluoro-phényl-amino)-7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one dimaléate, preparation et utilisation du 9-[4-(3-chloro-2-fluoro-phényl-amino)-7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one dimaléate en tant que medicament
AU2013218119A1 (en) * 2012-02-09 2014-07-17 Boehringer Ingelheim International Gmbh Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes
EP2875020B1 (fr) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Procédé de pràparation de une sel d'acide fumarique de la 9-[4-(3-chloro-2-fluoro-phénylamino)-7-méthoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undécan-5-one
CA2933082C (fr) 2013-12-12 2018-06-26 Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd Derive de quinazoline
CN105017164A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氯结构的酪氨酸激酶抑制剂及用途
CN105130913A (zh) * 2015-08-25 2015-12-09 佛山市赛维斯医药科技有限公司 一类多取代的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN109608470A (zh) * 2018-12-17 2019-04-12 上海药明康德新药开发有限公司 叔丁基-9-氧亚基-2,5,8-三氮杂螺[3.5]壬烷-2-甲酸基酯的合成方法
CN109503579A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-9-甲酸基酯的制备方法
CN109485648A (zh) * 2018-12-17 2019-03-19 无锡合全药业有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
EA009300B1 (ru) 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
JP2008513476A (ja) 2004-09-17 2008-05-01 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｃ−Ｋｉｔ癌原遺伝子阻害剤としての（スピロシクリルアミド）アミノチオフェン化合物
JP2009518450A (ja) 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
TWI421070B (zh) 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
EP2245026B1 (fr) * 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour les produire
JP2012501991A (ja) * 2008-09-03 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルス性疾患の治療のためのキナゾリン誘導体の使用
EP2289881A1 (fr) 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Procédé de synthèse stéréo-sélective d'hétérocycles bi-cycliques
EP2670736B1 (fr) 2011-02-01 2017-03-15 Boehringer Ingelheim International GmbH 9-[4-(3-chloro-2-fluoro-phényl-amino)-7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one dimaléate, preparation et utilisation du 9-[4-(3-chloro-2-fluoro-phényl-amino)-7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one dimaléate en tant que medicament

Also Published As

Publication number Publication date
CL2013002031A1 (es) 2013-12-27
NZ613917A (en) 2015-08-28
AR085056A1 (es) 2013-08-07
CN103608336A (zh) 2014-02-26
JP2014504619A (ja) 2014-02-24
US8853225B2 (en) 2014-10-07
EP2670736A1 (fr) 2013-12-11
PE20141012A1 (es) 2014-09-10
KR20140011330A (ko) 2014-01-28
US20140371226A1 (en) 2014-12-18
WO2012104206A9 (fr) 2013-11-21
AP3531A (en) 2016-01-13
SG192216A1 (en) 2013-09-30
EA023573B1 (ru) 2016-06-30
CO6781555A2 (es) 2013-10-31
WO2012104206A1 (fr) 2012-08-09
EP2670736B1 (fr) 2017-03-15
CA2826193A1 (fr) 2012-08-09
AP2013006989A0 (en) 2013-07-31
BR112013019416A2 (pt) 2019-09-24
US20130030003A1 (en) 2013-01-31
UY33889A (es) 2012-08-31
EA201300872A1 (ru) 2014-01-30
GEP20156423B (en) 2016-01-11
US8906931B1 (en) 2014-12-09
TN2013000323A1 (en) 2015-01-20
MX2013008870A (es) 2013-08-14
ECSP13012847A (es) 2014-09-30
IL227534A0 (en) 2013-09-30
AU2012213556A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
MA34845B1 (fr) Dimaléate de 9-[4-(3-chloro-2- fluoro-phénylamino) -7-méthoxy-quinazoline-6-yloxy]-1,4-diazaspiro[5.5]undécane-5-one, son utilisation en tant que medicament et sa fabrication
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA30514B1 (fr) Nouveaux composes.
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
KR20150020170A (ko) Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
CL2010001467A1 (es) Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas.
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MX2009010881A (es) Compuestos farmaceuticos.
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
AU2009282962A8 (en) Compounds as kinase inhibitors
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
MA31171B1 (fr) Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
Mikolajczyk et al. 1, 2, 3, 4, 6‐Penta‐O‐galloyl‐β‐D‐glucose modulates perivascular inflammation and prevents vascular dysfunction in angiotensin II‐induced hypertension
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
JP2003525239A (ja) タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
Lim et al. Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis